| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.26 | 5e-12 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.24 | 5e-11 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.22 | 8e-11 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.22 | 8e-10 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.21 | 8e-09 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.2 | 6e-08 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.18 | 7e-08 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.18 | 1e-07 |